Norris Medicines Share Price Today

Norris Medicines shareholders pass all six resolutions at 35th AGM

All six resolutions at the 35th AGM were passed with requisite majorities. Mr. Vimal D. Shah's MD appointment passed with 99.37% valid vote support. Promoter votes were excluded as invalid for the interested-party resolution. Financial statements for FY26 and director reappointments received 99.59% support.

Norris Medicines holds 35th AGM on Sep 29 via VC; book closure Sep 23-29

Norris Medicines holds 35th AGM on Sep 29, 2026, via VC/OAVM at 2:30 pm. Remote e-voting runs from Sep 26 to Sep 28, 2026. Book closure period is Sep 23 to Sep 29, 2026. Voting cut-off date is Sep 22, 2026. Parva SharegISTRY facilitates e-voting process.

Norris Medicines FY26 Results: Net loss narrows 77% to ₹28.06 lakh

Net loss narrowed 77% YoY to ₹28.06 lakh in FY26. Revenue from operations surged 40% to ₹813.20 lakh. Auditors raised going concern doubts over negative working capital. Board seeks approval for ₹50 crore borrowing limit at AGM. Qualified audit opinion due to unprovided gratuity liability.

Norris Medicines Appoints Iqubal Ismail Patel as CFO and KMP

Norris Medicines Limited appointed Iqubal Ismail Patel as Chief Financial Officer and Key Managerial Personnel effective July 30, 2026, with Board approval granted on the same date following recommendations from the Audit Committee and Nomination and Remuneration Committee. Patel, a Graduate with over 11 years of association with the company, brings expertise in finance, accounts, taxation, budgeting, and financial planning, ensuring continuity in the company's financial strategy and governance.

Norris Medicines narrows FY26 net loss to ₹28.06 lakh

Norris Medicines Limited reduced its net loss to ₹28.06 lakh in FY26 from ₹123.75 lakh in the prior year, supported by a 39% increase in total income to ₹817.74 lakh. For the quarter ended March 31, 2026, the company reported a profit after tax of ₹5.06 lakh, reversing a loss of ₹22.85 lakh in the same period last year. The board approved the audited financial results on May 30, 2026, and appointed M/s. Dhiren Y Parikh & Co. as internal auditors for FY 2026–2027.

Norris Medicines Limited Announces Q3 FY26 Financial Results

Norris Medicines Limited's Board of Directors approved unaudited financial results for the quarter and year ended December 31, 2025, during a meeting held on February 14, 2026. The 30-minute board meeting was conducted in compliance with SEBI regulations, and the company plans to publish these results in newspapers as per regulatory requirements.